Desvenlafaxine Tablet, Extended Release
Product Images NDC 72603-556

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 72603-556). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Desvenlafaxine Extended-release Tablets 100 mg (NDC 72603-557-01)

Desvenlafaxine Extended-Release Tablets 100 mg label from NorthStar Rx LLC, displaying 90 tablets per bottle. The label includes storage instructions, usage guidelines to swallow whole, a reminder for pharmacists to dispense the Medication Guide, and manufacturing details including origin in India and manufacturer Rubicon Research Ltd.*

FDA Label Image

Desvenlafaxine Extended-release Tablets 25 mg - ndc 72603-555-01 (30s Tablets Label)

Desvenlafaxine Extended-Release Tablets 25 mg label for oral administration, containing 30 tablets. Manufactured for NorthStar Rx LLC and produced by Rubicon Research Ltd., India. The label includes dosage instructions, storage conditions, and a pharmacist advisory to dispense the Medication Guide separately.*

FDA Label Image

Desvenlafaxine Extended-release Tablets 50 mg (NDC 72603-556-01)

Label for Desvenlafaxine Extended-Release Tablets 50 mg by NorthStar Rx LLC. The label indicates a 30 tablet count and provides storage instructions, dosage form as oral extended-release tablets, and manufacturer details including Rubicon Research Ltd., India. The label also includes a pharmacist dispensing note and medication guide contact information.*

FDA Label Image

Desvenlafaxine Extended-release Tablets 50 mg (NDC 72603-556-02)

Desvenlafaxine Extended-Release Tablets 50 mg, oral extended-release tablets, 90 count, labeled for NorthStar Rx LLC. The label includes dosage information, storage instructions at 20° to 25°C, and manufacturer details including Rubicon Research Ltd. in India. The front label highlights the 50 mg strength in a yellow box and notes it is Rx only.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 1)

A forest plot chart displaying the geometric mean ratio (90% confidence interval) of pharmacokinetic parameters Cmax and AUC for desvenlafaxine under various conditions, including different levels of renal and hepatic impairment and demographic groups such as females and elderly age ranges. The chart compares changes relative to a reference value, showing variability in drug exposure.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 2)

A horizontal forest plot showing geometric mean ratios (90% confidence intervals) of Cmax and AUC for desvenlafaxine when coadministered with the CYP3A4 inhibitor ketoconazole. The plot presents change relative to reference values on a scale from 0.5 to 2.0, with Cmax near 1.08 and AUC near 1.43.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 3)

A forest plot chart showing the effect of Desvenlafaxine on the pharmacokinetics (Cmax, AUC) of interacting drugs, including Desipramine, Midazolam, Tamoxifen, and Aripiprazole. The chart displays geometric mean ratios with 90% confidence intervals for different dose levels of Desvenlafaxine, indicating the change relative to reference for each drug parameter.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 4)

A Kaplan-Meier curve comparing the estimated proportion of patients with relapse over time (days from randomization) between Desvenlafaxine 50 mg and placebo. The graph shows relapse percentages on the y-axis and time to relapse in days on the x-axis, with a blue solid line representing Desvenlafaxine 50 mg and a red dashed line representing placebo.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 5)

A line graph showing the estimated proportion of patients with relapse over time in days from randomization for Desvenlafaxine versus placebo. The x-axis represents the time to relapse (0 to 200 days), and the y-axis shows the proportion of patients with relapse in percentage. Desvenlafaxine is represented by a solid blue line with a lower relapse rate, while placebo is shown by a dashed red line with a higher relapse rate.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Structure)

Chemical structure of desvenlafaxine, showing molecular bonds and functional groups, including aromatic rings, hydroxyl groups, amine groups, carboxylic acids, and a water molecule (H2O).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.